Loading, please wait...
| EVALUATION LINK >> | REQUEST PARKING » | MAP & DIRECTIONS » |
RESIDENT SEMINAR SCHEDULE
Wednesday, December 16, 2020
St. Louis College of Pharmacy at University of Health Sciences and Pharmacy in St. Louis
Academic Research Building (ARB) and Virtually
|
|
ARB 337
|
ARB 406
|
ARB 469
|
|
SESSION 1
12:15 pm – 1:00 pm
|
Justin Liedke, Pharm.D Treatment of Distal Deep Vein Thrombosis (DVT) |
Julie Hubbard, Pharm.D.
Liver Transplant for Cholangiocarcinoma |
(Presenting Virtually)
Arsany Gadallah, Pharm.D.
The Use of Direct Oral Anticoagulants in Obese Patients |
|
1:00 pm – 1:05 pm
|
Break for Transition between Speakers
|
||
|
SESSION 2
1:05 pm – 1:50 pm
|
Karishma Desai, Pharm.D.
The Use of Ketamine for Continuous Analgosedation in Critically Ill Patients |
Roberto Montealegre, Pharm.D.
Steroids in Acute Respiratory Distress Syndrome (ARDS) |
Samantha Grimm, Pharm.D.
Is there Benefit in Administering Sodium Bicarbonate Routinely to Patients with out of Hospital Cardiac Arrest? |
Please join us for the eight and final Resident Seminar session of the 2020-2021 academic year. Presented by PGY1 and PGY2 residents from within the St. Louis area, this series focuses on current therapeutic topics in the practice of pharmacy. All sessions will be held in the classrooms in the Academic & Research Building (ARB) on the third and fourth floors, as well as virtually.
* Participants may earn a maximum possible 0.75 contact hour of CPE credit per session. The maximum possible credit that can be earned is 1.50 contact hours. Participants must complete an evaluation to receive credit.
REGISTRATION & PARKING INFORMATION
Live registrations are submitted by RPDs and through survey monkey only. Due to a limited number of live available classroom spaces, a maximum of 22 people are allowed per classroom. Virtual registrations are limitless and completed through survey monkey. Please note, this event has multiple concurrent sessions.
Registration is free, but is required in advance. Due to limited space, only those participants who register before 5:00 PM on Friday, December 11, 2020 will be able to request parking access on campus.
PARKING: To request parking, please first register for your desired sessions. Then, complete the parking questionnaire using the link above, or complete your parking request by clicking here>>>. If you do not request parking on our campus, or if you do not submit your request by the deadline, you will be re-directed upon arrival.
HANDOUTS: Paper copies of handouts will be provided in each room as well as electronically on this website. Copies of PowerPoint slides are not provided. To access the handouts electronically, participants should ensure they are logged in before accessing this event. Click the + symbol beside the session, which will expand the module. A clickable text link to download the handout as a PDF file will be present.
ATTENDANCE: All live participants will be required to sign in on the paper sheets, located within each room. Paper sign-in sheets will be reconciled against completed evaluations. Attendance for the virtual sessions will be captured once a participant joins the session and will be reconciled with completed evaluations. Any sessions that you did not attend will be removed from your account within two weeks following the seminars.
CPE CREDIT: Immediately following the presentation, registered participants will receive an email with a link to the evaluation. Within one week after attending the session, participants must complete this online evaluation. The CPE Administrator will submit each participant’s NABP number and date of birth combination to CPE Monitor for continuing education credit, no later than two weeks after the live presentation. Only ONE session may be claimed for each time block. If multiple concurrent sessions are claimed, or if a session is claimed that is not reflected on the paper sign or the attendance roster within Microsoft Teams Meeting, the offending participant forfeits CE credit.
ATTENDANCE: All live participants will be required to sign in on the paper sheets, located within each room. Paper sign-in sheets will be reconciled against completed evaluations. Attendance for the virtual sessions will be captured once a participant joins the session and will be reconciled with completed evaluations. Any sessions that you did not attend will be removed from your account within two weeks following the seminars.
CPE CREDIT: Immediately following the presentation, registered participants will receive an email with a link to the evaluation. Within one week after attending the session, participants must complete this online evaluation. The CPE Administrator will submit each participant’s NABP number and date of birth combination to CPE Monitor for continuing education credit, no later than two weeks after the live presentation. Only ONE session may be claimed for each time block. If multiple concurrent sessions are claimed, or if a session is claimed that is not reflected on the paper sign or the attendance roster within Microsoft Teams Meeting, the offending participant forfeits CE credit.
It is recommended that participants log on and review the information under "My Account" prior to completing evaluations. The NABP ePID and date of birth fields must be accurate for credit reporting to occur. Participants are encouraged to check their NABP eProfiles for receipt of credit within two weeks of submitting their evaluation(s). If a participant notices an error in credit on their NABP e-profile, they are encouraged to contact Nicole Fields at Nicole.Fields@uhsp.edu soon as possible. To best comply with ACPE's CE credit reporting policy, the University of Health Sciences and Pharmacy is unable, for any reason, to award or correct CE credit if more than 60 days have passed from the event.
After one week, evaluations will close and CPE credit may no longer be claimed. If the deadline is missed or if a CE credit correction must be issued, an additional fee may be incurred for late submission - please see our policy, located on the FAQ page for details. Evaluations close December 22, 2020 at 11:59 PM (CDT).
SPECIAL ACCOMMODATIONS
Attendees of all abilities are welcome to participate. If you require reasonable accommodations, please notify Nicole Fields via email at Nicole.Fields@uhsp.edu in advance so that she may secure resources as soon as possible. Every effort will be made to make accommodations where necessary.
Date: Dec 16, 2020 12:00 PM - 02:00 PM
Fee
$0.00
CE Hours
4.50
Activity Type
- Knowledge
The presentation begins with a background on deep vein thrombosis, including discussing the natural history/progression of deep vein thrombosis. This helps to establish the risks and complications associated with distal DVT and helps understand what can happen when a distal DVT goes untreated. Then, a quick discussion of the guideline recommendations regarding this topic are included. Following this, three main questions are posed in order to help focus our search on primary literature:
- What is the difference in the risk of recurrence of VTE?
- What is the difference in the risk of PE?
- What is the difference in the risk of bleeding?
To help answer these questions, four main randomized, controlled trials are evaluated in terms of benefits of initiating anticoagulation treatment of distal DVT, risks of treatment, appropriate agents for use, and what duration of therapy is shown to be effective. Furthermore, a recent meta-analysis is used to help understand what this data tells us in aggregate. Combining this information helps us understand what treatment strategies are appropriate in terms of when and how to treat distal DVT.
Objectives
- Describe the risks and complications associated with untreated distal deep vein thrombosis (DVT).
- Discuss the evidence regarding the safety and efficacy of anticoagulation for distal DVT.
Speaker(s)/Author(s)
|
Justin Liedke, Pharm.D. |
Activity Number
0033-0000-20-089-L01-P
Date:
12/16/20
Time:
12:15 PM - 01:00 PM
CE Hours
0.75
Location
ARB 337 and Virtually
Liver transplantation for cholangiocarcinoma has been a topic of contention for several years due to the rate of tumor recurrence and death following transplantation. Until recently, cholangiocarcinoma was considered an absolute contraindication for liver transplant. Based on preliminary data from the University of Nebraska, the Mayo Clinic developed a neoadjuvant chemotherapy regimen given prior to transplant in combination with tailored post-transplant immunosuppression target to decrease tumor recurrence rates and improve mortality rates. Due to outcomes observed from this protocol, the United Network for Organ Sharing (UNOS) has developed MELD "exception criteria" for patients with cholangiocarcinoma to expedite time spent on the transplant waiting list. This was done due to the rapid progression of disease seen in cholangiocarcinoma and the potentially curative modality that transplantation would offer to this otherwise lethal disease state.
This presentation will review the current literature of liver transplantation in combination with neoadjuvant chemotherapy for cholangiocarcinoma - discussing risks and benefits of this protocol - and assess appropriateness of MELD exception criteria for this patient population.
Objectives
- Identify patients with cholangiocarcinoma (CCA) that would meet transplantation criteria after completion of The Mayo Protocol
- Select the appropriate neoadjuvant chemotherapy regimen for cholangiocarcinoma patients
Speaker(s)/Author(s)
|
Julie Hubbard, Pharm.D. |
Activity Number
0033-0000-20-086-L01-P
Date:
12/16/20
Time:
12:15 PM - 01:00 PM
CE Hours
0.75
Location
ARB 406 and Virtual
There is limited evidence to make clear-cut recommendations on Direct Oral Anticoagulant (DOAC) use in obese patients. Based on pharmacokinetic data, the influence of BMI/weight on pharmacokinetic (PK)/pharmacodynamic (PD) profiles appears to be agent specific, favoring certain DOACs over others due to altered PK properties in obesity. Yet, without prospective correlation to thrombotic events, it remains unclear how influential DOAC distribution and clearance in obese patients are on clinical outcomes. Thus, it would be improper to make recommendations based on PK/PD data alone without further investigation. Nonetheless, recent studies that are to be reviewed in this presentation show promising results with similar efficacy and safety outcomes in both atrial fibrillation (Afib) and venous thromboembolism (VTE) patients between DOACs and warfarin. The goal of this presentation is to help the audience identify pharmacokinetic and pharmacodynamic changes in obesity and their impact on DOAC use, evaluate the evidence regarding the utilization of DOACs in obese patients, and formulate evidence-driven recommendations for the use of DOACs in obesity.
Objectives
- Identify pharmacokinetic and pharmacodynamic changes in obesity and their impact on Direct Oral Anticoagulant (DOAC) use.
- Summarize the evidence regarding the utilization of DOACs in obese patients.
- Discuss evidence-driven recommendations for the use of DOACs in obesity.
Speaker(s)/Author(s)
|
Arsany Gadallah, Pharm.D. |
Activity Number
0033-0000-20-090-L01-P
Date:
12/16/20
Time:
04:00 PM - 05:00 PM
CE Hours
0.75
Location
ARB 469 and Virtually
Acute pain management and sedation are crucial aspects of the "ICU Triad" -- the concept that pain, delirium, and agitation are all connected and have affects on one another. Improper and inadequate management of the ICU Triad can lead to in-hospital complications such as increased mortality and delirium, increased risk of developing chronic pain, and decreased quality of life. The current paradigm present in practice includes appropriate management of patients with hemodynamic and respiratory compromise, patients at an increased risk of delirium, patients with opioid tolerance, over-sedation, and physiologic dependence.
Ketamine is re-emerging in practice as it provides unique benefits to certain mechanically-ventilated populations in the ICU setting, however its use is not well outlined in the current SCCM Clinical Practice Guidelines.
My aim of this CE activity is to provide my audience with primary literature-based evidence to help pharmacists understand and implement the use of ketamine in the ICU.
Ketamine is re-emerging in practice as it provides unique benefits to certain mechanically-ventilated populations in the ICU setting, however its use is not well outlined in the current SCCM Clinical Practice Guidelines.
My aim of this CE activity is to provide my audience with primary literature-based evidence to help pharmacists understand and implement the use of ketamine in the ICU.
Objectives
- Identify the benefits and adverse effects associated with the use of ketamine in mechanically ventilated, critically-ill patients.
- Compare the use of continuous ketamine infusions in the ICU with the standard of care and its impact on analgosedation management.
- Summarize the data related to the efficacy and safety of ketamine as an option for analgosedation in mechanically ventilated patients in the ICU.
Speaker(s)/Author(s)
|
Karishma Desai, Pharm.D. |
Activity Number
0033-0000-20-088-L01-P
Date:
12/16/20
Time:
01:05 PM - 01:50 PM
CE Hours
0.75
Location
ARB 337 and Virtually
This session will review the early and new literature pertaining to corticosteroid use in the setting of ARDS. I will be discussing the pathophysiology of ARDS, risks and benefits of steroid use, dosing regimens, effects of early vs late initiation of steroids, and duration of regimens. I will also discuss future directions of ARDS research as it pertains to glucocorticoid use.
Objectives
- Identify the place in therapy for corticosteroids in ARDS .
- Compare and contrast the hyperinflammatory and hypoinflammatory phenotypes of ARDS.
Speaker(s)/Author(s)
|
Roberto Montealegre, Pharm.D. |
Activity Number
0033-0000-20-087-L01-P
Date:
12/16/20
Time:
01:05 PM - 01:50 PM
CE Hours
0.75
Location
ARB 406 and Virtually
There has been a longstanding debate on if a patient with out of hospital cardiac arrest should be routinely administered sodium bicarbonate. In the past, ACLS and AHA guidelines supported the use of sodium bicarbonate, however, updated guidelines recommend against it. Some literature suggests that the routine use of sodium bicarbonate increases the percentage of return of spontaneous circulation. Other literature disputes the notion that routine use of sodium bicarbonate is beneficial and suggests that its use is in fact harmful. This seminar will focus on patient survival and neurological function in patients who experienced out of hospital cardiac arrest and were administered sodium bicarbonate versus those who received standard care to assess its place in therapy.
Objectives
- Identify patients that may benefit from sodium bicarbonate administration in the setting of cardiac arrest.
- Describe the clinical outcomes seen in the literature that may support the use of sodium bicarbonate in cardiac arrest patients.
Speaker(s)/Author(s)
|
Samantha Grimm, Pharm.D. |
Activity Number
0033-0000-20-042-L01-P
Date:
12/16/20
Time:
01:05 PM - 01:50 PM
CE Hours
0.75
Location
ARB 469 and Virtually
